Artificial intelligence (AI)-powered cell capture startup Deepcell Inc. scooped up $20 million in a series A round led by Bow Capital. The funds are earmarked for developing the company’s microfluidics-based technology, building out a cell morphology atlas of more than 400 million cells and advancing a hypothesis-free approach to cell classification and sorting.
The Lung Cancer Genomic Screening Project for Individualized Medicine in Asia (LC-SCRUM-Asia) has partnered with Thermo Fisher Scientific Inc. to speed molecular profiling in two major studies. The project now uses Waltham, Mass.-based Thermo Fisher’s Ion Torrent Genexus system and Oncomine Precision assay as the sole system for conducting next-generation sequencing (NGS) to improve personalization of therapeutic approaches and better understand drug resistance in non-small-cell lung cancer (NSCLS).
Rarecyte Inc., a Seattle-based company making products for tissue and cell analysis, reported picking up $22 million in a series F financing round led by Healthquest Capital.
Rarecyte Inc., a Seattle-based company making products for tissue and cell analysis, reported picking up $22 million in a series F financing round led by Healthquest Capital. Also participating in the round were existing investors 5AM Ventures and Ron Seubert, Rarecyte’s founder and chief technology officer. The company plans to use the funds to expand global sales of its instruments and consumables platform in research clinical markets.
Chinese researchers have developed the first green tea-triggered genetic control system for future gene- and cell-based precision medicine applications, and then used it to treat diabetes in mice and monkeys, they reported in the Oct. 23, 2019, issue of Science Translational Medicine.
Tenaya Therapeutics Inc. CEO Faraz Ali told BioWorld that the company, which raised $92 million in a series B round, has programs from three cardiac platforms "stacked on top of each other" and wants to enter the clinic by the end of 2021 "with at least one of the multiple projects we're advancing." The South San Francisco-based firm wanted not to "let resources be the barrier" as to which goes first, he said. "We wanted the science to dictate that."
Francis Collins, director of the U.S. NIH, said in a public forum that his agency is "really bullish" about precision medicine. Precision medicine requires mounds of data to be viable; however, the necessary data may soon be available. Collins said the NIH's All of Us research program has drawn the interest of more than 300,000 willing participants to date, adding that the target enrollment of 1 million should be accomplished before the end of 2022.
Francis Collins, director of the U.S. NIH, said in a public forum that the agency is "really bullish" about precision medicine. However, while precision medicine requires mounds of data, which soon may be available, Collins said the NIH All of Us research program has drawn the interest of more than 300,000 willing participants to date, adding that the target enrollment of 1 million should be accomplished before the end of 2022.
SAO PAULO, Brazil – Latin America is following the lead of other developed markets by ramping up its focus on personalized medicine, but there are challenges, including the higher costs of those medicines and a lack of regulations.
